News Release

Zogenix to Participate in the Leerink Swann Hot Topics in Therapeutics Roundtable Conference


SAN DIEGO, Feb 8, 2011 (GlobeNewswire via COMTEX) --

Zogenix, Inc. (Nasdaq:ZGNX) today announced that Chief Executive Officer Roger L. Hawley, along with Executive Vice President and Chief Financial Officer Ann Rhoads, will participate in the Leerink Swann Hot Topics in Therapeutics Roundtable Conference to be held February 16-17, 2011 at The Roosevelt Hotel in New York City.

During the Conference, Mr. Hawley will also represent Zogenix on a panel of executives from leading neurology/pain companies. Mr. Hawley and Ms. Rhoads will be available to respond to questions and to participate in one-on-one meetings with investors attending the conference.

  Event:  Leerink Swann Hot Topics in Therapeutics Roundtable Conference

  Date:   Thursday, February 17, 2011

  Time:   10:25am ET (presentation); 11:00am ET (Neuro/Pain panel)

  Place:  The Roosevelt Hotel, New York, NY (Terrace Ballroom, lobby level)

The presentation will be web cast live and archived for 90 days on Zogenix' Investor Relations website at The panel discussion will not be web cast.

About Zogenix

Zogenix, Inc. (Nasdaq:ZGNX), with offices in San Diego and Emeryville, California, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Zogenix's first commercial product, SUMAVEL(R) DosePro(TM) (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache. Zogenix's lead product candidate, ZX002, is a novel, oral, single-entity controlled-release formulation of hydrocodone currently in Phase 3 clinical trials for the treatment of moderate to severe chronic pain in patients requiring around-the-clock opioid therapy.

For additional information, please visit

This news release was distributed by GlobeNewswire,

SOURCE: Zogenix

Sara Pellegrino
The Ruth Group
Jason Rando
The Ruth Group